Microbiota and Neurological Disorders: A Gut Feeling

Citation

Published Version
doi:10.1089/biores.2016.0010

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662270

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Microbiota and Neurological Disorders: A Gut Feeling

Walter H. Moos1,*, Douglas V. Faller2,3 David N. Harpp4 Iphigenia Kanara5,6 Julie Pernokas7 Whitney R. Powers8,9 and Kosta Steliou3,10,*

Abstract

In the past century, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide. Trillions of commensal microbes live in and on our body, and constitute the human microbiome. The vast majority of these microorganisms are maternally derived and live in the gut, where they perform functions essential to our health and survival, including: digesting food, activating certain drugs, producing short-chain fatty acids (which help to modulate gene expression by inhibiting the deacetylation of histone proteins), generating anti-inflammatory substances, and playing a fundamental role in the induction, training, and function of our immune system. Among the many roles the microbiome ultimately plays, it mitigates against untoward effects from our exposure to the environment by forming a biotic shield between us and the outside world. The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host–microbiome intermetabolic and crosstalk pathways has come to the forefront in studying therapeutic design. As reviewed in this report, synthetic biology shows potential in developing microorganisms for correcting pathogenic dysbiosis (gut microbiota–host maladaptation), although this has yet to be proven. However, the development and use of small molecule drugs have a long and successful history in the clinic, with small molecule histone deacetylase inhibitors representing one relevant example already approved to treat cancer and other disorders. Moreover, preclinical research suggests that epigenetic treatment of neurological conditions holds significant promise. With the mouth being an extension of the digestive tract, it presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Taken together, the data outlined herein provide an encouraging roadmap toward important new medicines and companion diagnostic platforms in a wide range of therapeutic indications.

Key words: α-lipoic acid; autism; dementia; dysbiosis; epigenetic; exercise; fatty acids; histone deacetylase; immune system; microbiota; mitochondria; neurodegenerative; probiotics; schizophrenia; synthetic biology

1Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, California.
2Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
3Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts.
4Department of Chemistry, McGill University, Montreal, Canada.
5Weatherhead Center for International Affairs, Harvard University, Cambridge, Massachusetts.
6Consulate General of Greece in Boston, Boston, Massachusetts.
8Department of Health Sciences, Boston University, Boston, Massachusetts.
9Department of Anatomy, Boston University School of Medicine, Boston, Massachusetts.
10PhenoMatriX, Inc., Boston, Massachusetts.

*Address correspondence to: Walter H. Moos, PhD, Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, 600 16th Street, Mail Code 2280, Genentech Hall 5512D, Mission Bay Campus, San Francisco, CA 94158, E-mail: walter.moos@ucsf.edu, moosw@cal.berkeley.edu; or Kosta Steliou, PhD, PhenoMatriX, Inc., 9 Hawthorne Place Suite 4R, Boston, MA 02114, E-mail: steliou@bu.edu, ksteliou@partners.org

© Walter H. Moos et al. 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Introduction
In less than 100 years, noncommunicable diseases have surpassed infectious diseases as the principal cause of sickness and death, worldwide.1 One hundred trillion commensal microbes (including the fungal community referred to as the mycobiome)2 that live in and on our body constitute the human microbiome,3 although a recent study4 estimates the overall figure to be much lower. Regardless of the absolute number, the vast majority of these microorganisms live in the gut (microbiota),5 where they perform functions that are essential to our health and survival. They help us digest food6; participate in the activation of certain drugs7; produce short-chain fatty acids (SCFAs) that help modulate gene expression by inhibiting deacetylation of histone proteins8–10; generate molecules that reduce inflammation11; and play a fundamental role in the induction, basic development, training, and function of our immune system.12–14 Thus, as a whole, the microbiome becomes an integral part of our immune makeup, and is largely inherited from the mother with significant differences consequent to cesarean versus vaginal deliveries.15–20 Among the many roles the microbiome may ultimately play in health and disease, it mitigates against the untoward effects from our exposure to the environment by residing as a biotic barrier between us and the world around us.1,21–25

Neuropsychiatric disorders26 are on the increase globally and, of the noncommunicable diseases, stand out as a leading cause of disability.3,8,27,28 Accruing evidence strongly links gut dysbiosis (gut microbiota–host maladaptation) as a risk factor in a wide range of mental illnesses that include neuropsychiatric conditions,3,29–38 such as autism spectrum disorder (ASD)39–46 and schizophrenia39,40,46–49 among them. There are currently no drugs approved that treat the core symptoms of ASD.50 The pathogenic mechanisms underlying schizophrenia, a debilitating mental disorder, are unknown51 and drug therapies used to treat the associated psychotic symptoms have advanced little since the introduction of clozapine in 1960.52,53

The reported association of mental illness with digestive disturbances dates back to Hippocrates and stands as the single consistently linked comorbidity described in the medical literature from ancient times to the present.49 Although the genesis of our microbiome is predominantly our mother’s,18,54 eventually our microbiome transforms into our own unique signature.55 Changes in the gut microbial composition and function constantly adapt to our diet,56,57 and the mechanistic relationships between the gut microbiota in the development of the enteric nervous system58 and the preservation of our metabolic health59,60 are only now beginning to be elucidated.

Microbiota-Induced Epigenetics
Advances in genetic editing technologies may help clarify whether it is our genetics that control our epigenome or epigenetics that control the genome—or, more likely, the relationship between the two is mutual.61 There is supporting evidence to suggest that our microbiome plays a fundamental role in this relationship.14,62,63 Numerous studies64,65 show microbe-generated metabolites are intertwined with host cell biochemistry and physiology, and SCFA-mediated cell signaling is a key pathway that gut microbes use to communicate with the host.9,44,66–68 Acetate, propionate (propionic acid is also commonly referred to as PPA), butyrate, and pentanoate, having respectively, 2, 3, 4, and 5 carbon atoms are SCFAs (Table 1), largely produced by microbial fermentation of complex polysaccharides (starches and fibers) in the colon (longer chain aliphatic acids with 6 to 12 carbons are considered to be medium-chain fatty acids [MCFAs]). SCFAs are absorbed into the bloodstream through the portal circulation of the host and/or the distal colon and are transported to recipient tissues where they are taken up and used in a variety of cellular responses, including the regulation of gene expression.9,47,74,75

Many brain disorders are associated with imbalances in protein acetylation levels and transcriptional dysfunction.76 Histone deacetylase (HDAC) inhibitors represent a promising therapeutic option to correct these deficiencies, and numerous studies using butyrate, the most potent of the SCFA HDAC inhibitors,9,77

Table 1. Chemical Structures of Fatty Acids with Two to Eight Carbon Atoms

<table>
<thead>
<tr>
<th>R</th>
<th>Fatty acid</th>
<th>No of carbon atoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>Acetic</td>
<td>2</td>
</tr>
<tr>
<td>CH₃</td>
<td>Propionic</td>
<td>3</td>
</tr>
<tr>
<td>CH₃CH₂</td>
<td>Butyric</td>
<td>4</td>
</tr>
<tr>
<td>CH₃CH₂CH₃</td>
<td>Pentanoic</td>
<td>5</td>
</tr>
<tr>
<td>CH₃CH₂CH₃CH₃</td>
<td>Hexanoic</td>
<td>6</td>
</tr>
<tr>
<td>CH₃CH₂CH₃CH₃CH₃</td>
<td>Heptanoic</td>
<td>7</td>
</tr>
<tr>
<td>CH₃CH₂CH₃CH₃CH₃CH₃</td>
<td>Octanoic</td>
<td>8</td>
</tr>
</tbody>
</table>
demonstrate the medicinal potential of butyrate in the intervention of neurodegenerative diseases and psychiatric disorders.26,64,76,78–85

α-Lipoic acid [(R)-5-(1,2-dithiolan-3-yl)pentanoic acid] (ALA, Fig. 1) is a naturally occurring 5-membered ring disulfide-substituted SCFA HDAC inhibitor,86,87 with strong antioxidant activity.88 It is an essential cofactor in aerobic metabolism and is the central component forming the pyruvate dehydrogenase complex,89,90 which functionally links glycolysis in the cytoplasm to oxidative phosphorylation (OXPHOS) in mitochondria.91 ALA plays a role in microbial metabolism too.92 Although ALA is present in almost all food types that we eat,93 and is readily digested, absorbed, and transported to tissues, including brain,94–96 the amounts available from diet are low.93 Although the acquisition and use of ALA vary in different microbes, yeast, and animal cells,97,98 its functions are, nonetheless, essential to the organism, and in most prokaryotic and eukaryotic microorganisms, plant and animal mitochondria, and plant plastids, ALA is enzymatically synthesized endogenously from the MCFA, octanoate.97–99

In addition to its role in the metabolic pathways, ALA is reported in many research studies to be a potent activator of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) antioxidant response element signaling pathway that regulates the expression of genes whose protein products are involved in the detoxification and elimination of reactive oxygen species and electrophilic agents.26,96,100–102 Oxidative stress has been implicated in the pathogenesis of various neurodegenerative and neuropsychiatric disorders, including depression.103,104 Vasconcelos et al.105 showed that ALA (100 mg/kg) alone or combined with clozapine reversed schizophrenia-like alterations induced by ketamine. Ketamine is a known glutamatergic N-methyl-D-aspartate receptor antagonist that can induce psychotomimetic, perceptual, cognitive, and neuroendocrine responses in humans and in rodent models of schizophrenia.106,107 ALA also inhibits nuclear factor kappa-B (NF-κB) activation independent of its antioxidant function. NF-κB belongs to an important group of transcription factors regulated by a kinase-mediated signaling pathway that transduces signals from the cell surface to changes in gene expression.108,109

Fatty acids represent one of the body’s long-term storage reservoirs and sources of fuel energy—the heart being a primary consumer.110 In the presence of respiratory oxygen, fatty acids are shuttled through the mitochondrial OXPHOS complex system, where they are degraded by two carbon units at a time to shorter-chain fatty acids (and ultimately to acetyl coenzyme A), with concomitant release of water, CO2, and ATP in the process. The cellular availability of SCFAs for use in epigenetic chromatin remodeling through their ability to inhibit HDAC activity, therefore, is closely tied to mitochondrial energy production and metabolism. Since both prokaryote and eukaryote cells share common pathways for energy production, for example, the citric acid cycle,75 it comes as no surprise that gut microbiota inexorably affect host-cell bioenergetics, which in turn fuels gene expression in the mitochondrial and nuclear genomes.75,111 Over a billion years of evolutionary history have allowed our mitochondrial DNA (mtDNA) and nuclear DNA to co-evolve with a high degree of genetic compatibility.112,113 Interestingly, our microbiome and our mitogenome (mtDNA), as well as portions of our epigenome—for example, maternal silencing,114 are uniquely passed to each of us from our mother.

Gut microbiota have a profound influence on the host immune system.13 Maternal immune activation is a shared environmental risk factor for a plethora of neuropsychiatric and neurodegenerative disorders that may or may not develop into clinical symptoms in offspring.13 Evidence from an in-depth study115 of data extracted from the Danish health registry of more than 1 million children born between 1980 and 2005, focusing on cases where the mother had a viral infection with fever requiring hospitalization during the first trimester, strongly links maternal immune dysregulation with suppressed neurodevelopment and cognitive function (ASD) in their offspring.116 In other epidemiological studies,117 prenatal exposure to infection visibly stands out as a risk factor in schizophrenia and other neurodevelopmental abnormalities. The possibility that prenatal Zika virus infection from a mosquito reservoir is responsible for the current outbreak in Brazil of children born with microcephaly is a disturbing and frightening example.118–121

---

**FIG. 1.** Chemical structure of R-(+)-lipoic acid.
**Synthetic Biology**

With a capacity to act either naturally or by manipulation, the gut microbial ecosystem is an indispensable and constituent player in the maintenance of our well-being. Thus, in treating disease, adjusting the functional composition of the gut microbiome may help facilitate and even alter the outcome of therapeutic interventions. Dietary sources of probiotics such as, for example, in traditional Greek yogurt, have been used since antiquity in the Mediterranean region (Mediterranean diet) to maintain a state of wellness. However, once pathogenic dysbiosis sets in, probiotics have not proven to be remedial and other interventional methods are being investigated. In this effort, independent work from several groups suggests that (engineered) bacteria have potential to be an effective means for delivering, enhancing, or themselves acting as therapeutic agents (“living pills”) to treat certain diseases including psychiatric disorders, and significant investments are being made to adapt a variety of commensal microbial species for remodeling the gut microbiota in disease-treating indications. A similar approach aims to utilize engineered viruses to seek and selectively destroy pathogenic bacteria. Drawing conclusions from a study of 11 children affected by ASD that (engineered) bacteria have potential to be an effective means for delivering, enhancing, or themselves acting as therapeutic agents (“living pills”) to treat certain diseases, and significant investments are being made to adapt a variety of commensal microbial species for remodeling the gut microbiota (ecobiotics) in disease-treating indications.

Aging is a leading risk factor in progressing to dementia. Although the latest studies suggest that the prevalence of dementia may be leveling off and even decreasing in some subsets of the population, for the foreseeable future, dementia will continue to be a major challenge for the healthcare establishment. The gut’s evolving capacity to adapt and maintain normal microbiota, which begins at birth and continues throughout one’s life, is necessary to support the metabolic activities of the brain, and schizophrenia, can be modulated by reconfiguring the gut microbiome composition. Acetate, propionate, and butyrate comprise the majority of SCFAs produced in the gut by microbial fermentation. Propionate and butyrate can modulate brain functioning, principally appetite and energy homeostasis, through regulation of neuropeptide production. Butyrate is mostly absorbed by the colonic epithelium, whereas acetate and propionate are passed into the portal circulation. In gut dysbiosis, the constitutional spectrum of SCFAs varies substantially from the host’s natural healthy balance, and higher than normal levels of PPA have been linked to deleterious effects on brain function in autistic children. Given these findings, and the fact that PPA is widely used as a food preservative, there may be cause for some concern.

Idiopathic late-onset dementia (ILOD) is characterized by a series of declining daily functional competences, most often involving memory, reasoning, and sociobehavioral abilities, in the elderly. Dementia encompasses a myriad of clinical symptoms typically associated with discrete neurological disorders such as Alzheimer and Parkinson diseases, hippocampal sclerosis of aging, and Lewy body and frontotemporal dementias.
being the more notable ones, but not collectively manifested by any one of them. Cellular processes depend on the energy supplied by their mitochondria, and dysfunctional mitochondria can lead to an unsustainable cellular bioenergetics deficit that is detrimental to the cell’s function and survival.¹⁸¹ In brain cells, even a small energy deficit, which is a common occurrence during the aging process, can reduce synaptic neurotransmitter release and adversely affect synaptic function.²⁶,¹⁰¹ Maintaining a healthy gut microbiota state is necessary to support the metabolic activities of the brain,⁵⁹,¹⁶² and Mattson¹⁵⁷ and Bourassa et al.⁸⁵ posit that some of the common pathologies leading to ILOD and other brain disorders may be amenable to therapeutic modification by diet and lifestyle changes. For example, exercise, yoga, and meditation are lifestyle activities known to improve brain blood flow—which, presumably, can enhance perfusion of the brain with micronutrients absorbed by the gut¹⁸²—and are increasingly being incorporated in treatments for depression and other mental disturbances.⁶⁶,¹²⁷,¹⁸³–¹⁸⁵

At the other end of the age spectrum, the correlation between impaired intellectual development and a prolonged state of malnutrition in infants and young children is inescapable.¹⁸⁶–¹⁸⁹ Recent studies have demonstrated that the normal pattern of gut microbiota assembly is disrupted in malnourished children.¹⁶²,¹⁸⁷ To maximize the therapeutic benefit of diet and dietary supplements, preclinical evidence suggests that a healthy microbiome in these children may need to be configured as well.¹⁹⁰,¹⁹¹

**Concluding Remarks**

The importance of physical activity coupled with a balanced and healthy diet in the maintenance of our well-being has been recognized since antiquity. However, it is only recently that characterization of the host–microbiome intermetabolic and crosstalk pathways has come to the forefront for study in therapeutic design and treatments.⁶⁸,¹⁹² As reviewed in this report, synthetic biology has potential to develop microorganisms for correcting pathogenic dysbiosis, but this has yet to be proven. (For additional examples of the latest approaches to manipulating the microbiota, including illustrative figures, see Ash and Mueller,¹⁹³ and articles cited therein.) In contrast, the development and use of small molecule drugs have a long and successful history in the clinical treatment of diseases. Small molecule HDAC inhibitors are already used in the clinic to treat cancer and hematological disorders,⁷⁷ and preclinical research with SCFA HDAC inhibitors demonstrates significant potential in epigenetic treatment of neurological conditions.²⁶,¹⁰¹ Epigenetic regulation of host–microbiota interactions by utilizing epigenomic-targeting drugs has been suggested by Alenghat and Artis.⁷⁴

---

**FIG. 2.** Meta analyzed estimates of dementia prevalence in the United States.
The mouth, being an extension of the digestive tract, presents a readily accessible diagnostic site for the early detection of potential unhealthy pathogens resident in the gut. Salivonomics is a rapidly emerging tool in the arsenal of salivary diagnostics. Collecting saliva or swabbing the inside cheek of the mouth is noninvasive, making it a highly attractive diagnostic procedure, particularly for infants and young children. It is not unlikely that regular visits to your dentist may soon be as important to your gut as it is to your oral hygiene, white teeth, and a nice smile.

**Acknowledgments**

We thank the MitoCure Foundation for their generous financial support, and Drs. Carl A. Pinkert (The University of Alabama, Tuscaloosa, AL), Michael H. Irwin (Auburn University, Auburn, AL), Robert J. Zamboni (McGill University, Montreal, QC, Canada), and Susan P. Perrine (Boston University School of Medicine) for their invaluable advice and helpful discussions in the preparation of this article.

**Authors’ Contributions**

The article was written through contributions of all authors. All authors have given approval to the final version of the article.

**Author Disclosure Statement**

K.S. owns shares in PhenoMatriX. W.H.M. and K.S. have collaborated in the past on cancer projects as part of a formal agreement between SRI International and PhenoMatriX. No competing financial interests exist.

**References**

Moos, et al.; BioResearch Open Access 2016, 5.1
http://online.liebertpub.com/doi/10.1089/biores.2016.0010


100. Do¨ rsam B, Fahrer J. The disulfide compound Moos, et al
120. Estes ML, McAllister AK. Maternal T H17 cells take a toll on baby’s brain.
116. Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in
110. Beauloye C, Horman S, Bertrand L. Even is better than odd: one fat may
107. Lafioniatis A, Orfanidou MA, Papadopoulou ES, et al. Effects of the in-
106. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the non-
104. Silva MCC, de Sousa CNS, Gomes PXL, et al. Evidence for protective ef-
103. Lombard JH. Depression, psychological stress, vascular dysfunction, and
102. Prasad KN. Simultaneous activation of Nrf2 and elevation of dietary and
101. Irwin MH, Moos WH, Faller DV, et al. Epigenetic treatment of neurode-
122. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of
121. Siczinski, Foster JA. Infect. Dis. and the gut–brain axis: in the pursuit of

157. Mattson MP. Late-onset dementia: a mosaic of prototypical pathologies
156. Currais A. Ageing and inflammation–A central role for mitochondria in
104. Silva MCC, de Sousa CNS, Gomes PXL, et al. Evidence for protective ef-
103. Lombard JH. Depression, psychological stress, vascular dysfunction, and
102. Prasad KN. Simultaneous activation of Nrf2 and elevation of dietary and
101. Irwin MH, Moos WH, Faller DV, et al. Epigenetic treatment of neurode-
122. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of
121. Siczinski, Foster JA. Infect. Dis. and the gut–brain axis: in the pursuit of

135. Zuccarello, F, Petty, J. Infect. Dis. and the gut–brain axis: in the pursuit of
132. Bauchl, C, Homan, S, Bertrand, L. Even is better than odd: one fat may
131. Beauloye, C, Horman, S, Bertrand, L. Even is better than odd: one fat may
130. Ying, Z, Kampfrath, T, Sun, Q, et al. Evidence that alpha-lipoic acid inhibits
129. Ying, Z, Kampfrath, T, Sun, Q, et al. Evidence that alpha-lipoic acid inhibits

100. Dörsam B, Fahrer J. The disulfide compound z-lipoic acid and its deriva-
101. Irwin MH, Moos WH, Faller DV, et al. Epigenetic treatment of neurode-
102. Prasad KN. Simultaneous activation of Nr2 and elevation of dietary and
103. Lombard JH. Depression, psychological stress, vascular dysfunction, and
104. Silva MCC, de Sousa CNS, Gomes PXL, et al. Evidence for protective ef-
105. Siczinski, Foster JA. Infect. Dis. and the gut–brain axis: in the pursuit of
106. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the non-
107. Lafioniatis A, Orfanidou MA, Papadopoulou ES, et al. Effects of the in-
110. Beauloye C, Horman S, Bertrand L. Even is better than odd: one fat may
113. Beauloye C, Homan S, Bertrand L. Even is better than odd: one fat may
114. Shenderov BA, Midvedt T. Epigenomic programming: a future way to
116. Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in
117. Johnston IG, Williams BP. Evolutionary inference across eukaryotes
118. Wilkins JF, Ubeda F, Van Cleve J. The evolving landscape of imprinted
genomes in humans and mice: conflict among alleles, genes, tissues, and
120. Estes ML, McAllister AK. Maternal T H17 cells take a toll on baby’s brain.
121. Bauchl, C, Homan, S, Bertrand, L. Even is better than odd: one fat may
122. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of
125. Babio N, Becerra-Tomás N, Martínez-González MA, et al. Consumption of
and its effect on neuropsychiatric disorders with suspected immune
127. Klein N. Kemper KJ. Integrative approaches to caring for children with
print]: DOI: 10.1016/j.cppeds.2015.12.004.

180. Shultz SR, Aziz NAB, Yang L, et al. Intracerebroventricular injection of
178. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
177. Foley KA, MacFabe DF, Kavaliers M, et al. Sexually dimorphic effects of
175. Galland L. The gut microbiome and the brain. J Med Food,
173. MacFabe DF Short-chain fatty acid fermentation products of the gut
171. Marette A, Jobin C. SCFAs take a toll en route to metabolic syndrome.
170. Lee SH, de La Serre CB. Gut microbiome-brain communications regulate
166. Sampson TR, Mazmanian SK. Control of brain development, function,
164. Millan MJ, Andrieux A, Bartzkokis G, et al. Altering the course of schizo-
163. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
160. Wu Y-T, Fratiglioni L, Matthews FE, et al. Dementia in western Europe: epide-
158. Quaglio G, Brand H, Dario C. Fighting dementia in Europe: the time to act
154. MacFabe DF Short-chain fatty acid fermentation products of the gut
152. Millan MJ, Andrieux A, Bartzkokis G, et al. Altering the course of schizo-
151. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
150. Sampson TR, Mazmanian SK. Control of brain development, function,
147. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
146. Sampson TR, Mazmanian SK. Control of brain development, function,
144. Millan MJ, Andrieux A, Bartzkokis G, et al. Altering the course of schizo-
143. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
142. Sampson TR, Mazmanian SK. Control of brain development, function,
140. Millan MJ, Andrieux A, Bartzkokis G, et al. Altering the course of schizo-
139. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
138. Sampson TR, Mazmanian SK. Control of brain development, function,
135. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
134. Sampson TR, Mazmanian SK. Control of brain development, function,
131. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
130. Sampson TR, Mazmanian SK. Control of brain development, function,
127. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
126. Sampson TR, Mazmanian SK. Control of brain development, function,
123. Frye RE, Slattery J, MacFabe DF, et al. Approaches to studying and ma-
122. Sampson TR, Mazmanian SK. Control of brain development, function,